Nilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65405
下载链接
链接失效反馈官方服务：
资源简介：
To assess the safety, efficacy, and molecular change associated with treatment of patients with early, diffuse cutaneous systemic sclerosis (dcSSc) with nilotinib (Tasigna™). In this open-label pilot trial 6 adult patients with early dcSSc received nilotinib. Primary endpoints were safety and change in modified Rodnan Skin Score (MRSS) after 6 months. Lesional skin biopsies at baseline, 6 and 12 months of treatment were assessed by histopathology, immunohistochemistry, and DNA microarray.
创建时间：
2016-10-11
